Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report
Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate ca...
Gespeichert in:
| Veröffentlicht in: | Molecular and clinical oncology 2018-09, Vol.9 (3), p.339-341 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 341 |
|---|---|
| container_issue | 3 |
| container_start_page | 339 |
| container_title | Molecular and clinical oncology |
| container_volume | 9 |
| creator | Jehangir, Waqas Tulpule, Sunil Sanabria, Federico Bhatt, Harsh Zafar, Shoaib Osman, Mohamed Enakuaa, Souad Yousif, Abdalla |
| description | Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate cancer leading to MGUS has not been documented previously. MGUS is generally thought to be benign and has been demonstrated to convert into multiple myeloma (MM), as well as other lymphoproliferative disorders. Due to the high mortality rate associated with MM, further studies are required to confirm and clarify the association between prostate cancer and MGUS. Additionally, patients can be counseled on the requirement for follow up studies following a diagnosis of prostate cancer. |
| doi_str_mv | 10.3892/mco.2018.1674 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6109677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A553280348</galeid><sourcerecordid>A553280348</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-7e68c43bde2a9de2f9b5f7b329aca1c30842cb97cc8fcc5fb2d434ffddb3c7b53</originalsourceid><addsrcrecordid>eNptktFr1TAUxosobmx79FUCvvjSa5o0TeODcBm6CYP5sL0JIT096TLa5Jq0g_33pt55dWICOSH5nS_knK8o3lR0w1vFPkwQNoxW7aZqZP2iOGa0VqWqG_XysBf0qDhL6Z7moSRlQr0ujjithGBCHhffv8WQZjMjAeMBIxnR9M4PZA5kCj7AGLwZyWCmKezMfPdIgiWL73HGODmPPUlu8M66X-kfyTbrJCQRdyHOp8Ura8aEZ0_xpLj98vnm_LK8ur74er69KqGu2FxKbFqoedcjMyovVnXCyo4zZcBUwGlbM-iUBGgtgLAd62teW9v3HQfZCX5SfNrr7pZuwh7Qz9GMehfdZOKjDsbp5zfe3ekhPOimoqqRMgu8fxKI4ceCadaTS4DjaDyGJWmWMSF4U63ou3_Q-7DEXKM9xVrGFPtDDWZE7bwN-V1YRfU2C7GW8rrN1OY_VJ49Tg6CR-vy-bOEcp8AuWspoj38saJ6dYTOjtCrI_TqiMy__bswB_p3__lPwoKypg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2096282292</pqid></control><display><type>article</type><title>Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jehangir, Waqas ; Tulpule, Sunil ; Sanabria, Federico ; Bhatt, Harsh ; Zafar, Shoaib ; Osman, Mohamed ; Enakuaa, Souad ; Yousif, Abdalla</creator><creatorcontrib>Jehangir, Waqas ; Tulpule, Sunil ; Sanabria, Federico ; Bhatt, Harsh ; Zafar, Shoaib ; Osman, Mohamed ; Enakuaa, Souad ; Yousif, Abdalla</creatorcontrib><description>Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate cancer leading to MGUS has not been documented previously. MGUS is generally thought to be benign and has been demonstrated to convert into multiple myeloma (MM), as well as other lymphoproliferative disorders. Due to the high mortality rate associated with MM, further studies are required to confirm and clarify the association between prostate cancer and MGUS. Additionally, patients can be counseled on the requirement for follow up studies following a diagnosis of prostate cancer.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2018.1674</identifier><identifier>PMID: 30155257</identifier><language>eng</language><publisher>England: Spandidos Publications</publisher><subject>Back pain ; Blood pressure ; Bone marrow ; Care and treatment ; Case reports ; Case studies ; Complications and side effects ; Development and progression ; Family medical history ; Laboratories ; Lymphatic diseases ; Medical imaging ; Metastasis ; Multiple myeloma ; Oncology ; Paraproteinemias ; Patients ; Prostate cancer ; Proteins ; Studies ; Vital signs</subject><ispartof>Molecular and clinical oncology, 2018-09, Vol.9 (3), p.339-341</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright © 2018, Spandidos Publications 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-7e68c43bde2a9de2f9b5f7b329aca1c30842cb97cc8fcc5fb2d434ffddb3c7b53</citedby><cites>FETCH-LOGICAL-c412t-7e68c43bde2a9de2f9b5f7b329aca1c30842cb97cc8fcc5fb2d434ffddb3c7b53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109677/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109677/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30155257$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jehangir, Waqas</creatorcontrib><creatorcontrib>Tulpule, Sunil</creatorcontrib><creatorcontrib>Sanabria, Federico</creatorcontrib><creatorcontrib>Bhatt, Harsh</creatorcontrib><creatorcontrib>Zafar, Shoaib</creatorcontrib><creatorcontrib>Osman, Mohamed</creatorcontrib><creatorcontrib>Enakuaa, Souad</creatorcontrib><creatorcontrib>Yousif, Abdalla</creatorcontrib><title>Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate cancer leading to MGUS has not been documented previously. MGUS is generally thought to be benign and has been demonstrated to convert into multiple myeloma (MM), as well as other lymphoproliferative disorders. Due to the high mortality rate associated with MM, further studies are required to confirm and clarify the association between prostate cancer and MGUS. Additionally, patients can be counseled on the requirement for follow up studies following a diagnosis of prostate cancer.</description><subject>Back pain</subject><subject>Blood pressure</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>Case reports</subject><subject>Case studies</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Family medical history</subject><subject>Laboratories</subject><subject>Lymphatic diseases</subject><subject>Medical imaging</subject><subject>Metastasis</subject><subject>Multiple myeloma</subject><subject>Oncology</subject><subject>Paraproteinemias</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Proteins</subject><subject>Studies</subject><subject>Vital signs</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptktFr1TAUxosobmx79FUCvvjSa5o0TeODcBm6CYP5sL0JIT096TLa5Jq0g_33pt55dWICOSH5nS_knK8o3lR0w1vFPkwQNoxW7aZqZP2iOGa0VqWqG_XysBf0qDhL6Z7moSRlQr0ujjithGBCHhffv8WQZjMjAeMBIxnR9M4PZA5kCj7AGLwZyWCmKezMfPdIgiWL73HGODmPPUlu8M66X-kfyTbrJCQRdyHOp8Ura8aEZ0_xpLj98vnm_LK8ur74er69KqGu2FxKbFqoedcjMyovVnXCyo4zZcBUwGlbM-iUBGgtgLAd62teW9v3HQfZCX5SfNrr7pZuwh7Qz9GMehfdZOKjDsbp5zfe3ekhPOimoqqRMgu8fxKI4ceCadaTS4DjaDyGJWmWMSF4U63ou3_Q-7DEXKM9xVrGFPtDDWZE7bwN-V1YRfU2C7GW8rrN1OY_VJ49Tg6CR-vy-bOEcp8AuWspoj38saJ6dYTOjtCrI_TqiMy__bswB_p3__lPwoKypg</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Jehangir, Waqas</creator><creator>Tulpule, Sunil</creator><creator>Sanabria, Federico</creator><creator>Bhatt, Harsh</creator><creator>Zafar, Shoaib</creator><creator>Osman, Mohamed</creator><creator>Enakuaa, Souad</creator><creator>Yousif, Abdalla</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180901</creationdate><title>Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report</title><author>Jehangir, Waqas ; Tulpule, Sunil ; Sanabria, Federico ; Bhatt, Harsh ; Zafar, Shoaib ; Osman, Mohamed ; Enakuaa, Souad ; Yousif, Abdalla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-7e68c43bde2a9de2f9b5f7b329aca1c30842cb97cc8fcc5fb2d434ffddb3c7b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Back pain</topic><topic>Blood pressure</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>Case reports</topic><topic>Case studies</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Family medical history</topic><topic>Laboratories</topic><topic>Lymphatic diseases</topic><topic>Medical imaging</topic><topic>Metastasis</topic><topic>Multiple myeloma</topic><topic>Oncology</topic><topic>Paraproteinemias</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Proteins</topic><topic>Studies</topic><topic>Vital signs</topic><toplevel>online_resources</toplevel><creatorcontrib>Jehangir, Waqas</creatorcontrib><creatorcontrib>Tulpule, Sunil</creatorcontrib><creatorcontrib>Sanabria, Federico</creatorcontrib><creatorcontrib>Bhatt, Harsh</creatorcontrib><creatorcontrib>Zafar, Shoaib</creatorcontrib><creatorcontrib>Osman, Mohamed</creatorcontrib><creatorcontrib>Enakuaa, Souad</creatorcontrib><creatorcontrib>Yousif, Abdalla</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jehangir, Waqas</au><au>Tulpule, Sunil</au><au>Sanabria, Federico</au><au>Bhatt, Harsh</au><au>Zafar, Shoaib</au><au>Osman, Mohamed</au><au>Enakuaa, Souad</au><au>Yousif, Abdalla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>9</volume><issue>3</issue><spage>339</spage><epage>341</epage><pages>339-341</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate cancer leading to MGUS has not been documented previously. MGUS is generally thought to be benign and has been demonstrated to convert into multiple myeloma (MM), as well as other lymphoproliferative disorders. Due to the high mortality rate associated with MM, further studies are required to confirm and clarify the association between prostate cancer and MGUS. Additionally, patients can be counseled on the requirement for follow up studies following a diagnosis of prostate cancer.</abstract><cop>England</cop><pub>Spandidos Publications</pub><pmid>30155257</pmid><doi>10.3892/mco.2018.1674</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9450 |
| ispartof | Molecular and clinical oncology, 2018-09, Vol.9 (3), p.339-341 |
| issn | 2049-9450 2049-9469 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6109677 |
| source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Back pain Blood pressure Bone marrow Care and treatment Case reports Case studies Complications and side effects Development and progression Family medical history Laboratories Lymphatic diseases Medical imaging Metastasis Multiple myeloma Oncology Paraproteinemias Patients Prostate cancer Proteins Studies Vital signs |
| title | Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostate%20cancer%20leading%20to%20monoclonal%20gammopathy%20of%20undetermined%20significance:%20A%20case%20report&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=Jehangir,%20Waqas&rft.date=2018-09-01&rft.volume=9&rft.issue=3&rft.spage=339&rft.epage=341&rft.pages=339-341&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2018.1674&rft_dat=%3Cgale_pubme%3EA553280348%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2096282292&rft_id=info:pmid/30155257&rft_galeid=A553280348&rfr_iscdi=true |